Fusion Pharmaceuticals Inc.
FUSN
Price:
$21.55
Market Cap:
$1.83B
Fusion Pharmaceuticals Inc., a clinical-stage oncology company, focuses on developing radiopharmaceuticals as precision medicines. The company has developed Targeted Alpha Therapies platform together with its proprietary Fast-Clear linker technology to enable us to connect alpha particle emitting isotopes to various targeting molecules in order to selectively deliver the alpha particle payloads to tumors. Its lead product candidate is FPI-1434 that is in Phase 1 clinical trials as a monotherapy in patients with solid tumors expressing insulin-like growth factor 1 receptor. The company is also conducting additional preclinical studies of FPI-1434 in combination with approved checkpoint inhibi...[Read more]
Industry
Biotechnology
IPO Date
2020-06-26
Stock Exchange
NASDAQ
Ticker
FUSN
PE Ratio
[-15.39]
ROE
[-48.74%]
Current Ratio
[10.64]
Dividend Yield
[0%]
Enterprise Value
[1.87B]
Dividend History
The ROE as of November 2024 (TTM) for Fusion Pharmaceuticals Inc. (FUSN) is -48.74%
According to Fusion Pharmaceuticals Inc.’s latest financial reports and current stock price. The company's current ROE is -48.74%. This represents a change of 304.95% compared to the average of -12.04% of the last 4 quarters.
Fusion Pharmaceuticals Inc. (FUSN) Historical ROE (quarterly & annually)
How has FUSN ROE performed in the past?
The mean historical ROE of Fusion Pharmaceuticals Inc. over the last ten years is -6.41%. The current -48.74% ROE has changed 659.90% with respect to the historical average. Over the past ten years (40 quarters), FUSN's ROE was at its highest in in the December 2019 quarter at 24.50%. The ROE was at its lowest in in the March 2020 quarter at -17.52%.
Average
-6.41%
Median
-26.60%
Minimum
-54.01%
Maximum
65.03%
Fusion Pharmaceuticals Inc. (FUSN) ROE by Quarter and Year
Discovering the peaks and valleys of Fusion Pharmaceuticals Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = Infinity%
Maximum Annual ROE = 65.03%
Minimum Annual Increase = -155.02%
Minimum Annual ROE = -54.01%
| Year | ROE | Change |
|---|---|---|
| 2023 | -42.65% | -21.02% |
| 2022 | -54.01% | 54.24% |
| 2021 | -35.02% | 31.65% |
| 2020 | -26.60% | -155.02% |
| 2019 | 48.34% | -25.66% |
| 2018 | 65.03% | Infinity% |
Fusion Pharmaceuticals Inc. (FUSN) Average ROE
How has FUSN ROE performed in the past?
The current ROE of Fusion Pharmaceuticals Inc. (FUSN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-43.89%
5-year avg
-21.99%
10-year avg
-6.41%
Fusion Pharmaceuticals Inc. (FUSN) ROE vs. Peers
How is FUSN’s ROE compared to its peers?
Fusion Pharmaceuticals Inc.’s ROE is greater than Bicycle Therapeutics plc (-27.35%), greater than Relmada Therapeutics, Inc. (-129.80%), greater than RAPT Therapeutics, Inc. (-89.09%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), greater than BioAtla, Inc. (-187.30%), greater than Passage Bio, Inc. (-72.53%), greater than PMV Pharmaceuticals, Inc. (-24.20%), greater than Ikena Oncology, Inc. (-39.59%), greater than Olema Pharmaceuticals, Inc. (-53.55%), less than Spero Therapeutics, Inc. (3.36%), greater than Bolt Biotherapeutics, Inc. (-69.46%), less than Coherus BioSciences, Inc. (0.40%), greater than Gracell Biotechnologies Inc. (-15.56%), greater than Neoleukin Therapeutics, Inc. (-8.54%), greater than Keros Therapeutics, Inc. (-41.74%), greater than Janux Therapeutics, Inc. (-10.46%), less than Fennec Pharmaceuticals Inc. (31.99%), greater than Edgewise Therapeutics, Inc. (-26.83%), less than Harmony Biosciences Holdings, Inc. (23.16%),
| Company | ROE | Market cap |
|---|---|---|
| -27.35% | $1.42B | |
| -129.80% | $84.49M | |
| -89.09% | $37.75M | |
| -53.79% | $1.87B | |
| -187.30% | $75.90M | |
| -72.53% | $31.19M | |
| -24.20% | $83.31M | |
| -39.59% | $82.52M | |
| -53.55% | $503.07M | |
| 3.36% | $63.24M | |
| -69.46% | $22.14M | |
| 0.40% | $125.58M | |
| -15.56% | $989.87M | |
| -8.54% | $8.20M | |
| -41.74% | $2.27B | |
| -10.46% | $2.64B | |
| 31.99% | $145.92M | |
| -26.83% | $3.05B | |
| 23.16% | $1.94B |
Build a custom stock screener for Fusion Pharmaceuticals Inc. (FUSN) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Fusion Pharmaceuticals Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Fusion Pharmaceuticals Inc. (FUSN) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Fusion Pharmaceuticals Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Fusion Pharmaceuticals Inc.'s ROE?
How is the ROE calculated for Fusion Pharmaceuticals Inc. (FUSN)?
What is the highest ROE for Fusion Pharmaceuticals Inc. (FUSN)?
What is the 3-year average ROE for Fusion Pharmaceuticals Inc. (FUSN)?
What is the 5-year average ROE for Fusion Pharmaceuticals Inc. (FUSN)?
How does the current ROE for Fusion Pharmaceuticals Inc. (FUSN) compare to its historical average?